Physicians' Academy for Cardiovascular Education
Dyskalemia was common in HF with different risk in HF subtypes. Hyperkalemia and hypokalemia were predicted by similar variables and incident dyskalemia was associated with increased mortality.
In a randomized trial, a program of supervised and home-based exercise training significantly improved exercise test duration but had no effect on clinical events with similar effects across baseline physical activity tertiles in HFrEF patients.
A prospective cohort study found that alcohol consumption of ≤7 drinks per week after the diagnosis of HF was associated with longer survival in adults with HF, compared to long-term abstinence.
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.
Patients with HF with LVEF >40% showed greater total epicardial fat content, which was not related to BMI. Epicardial fat volume was associated with the presence of AF and T2DM.
In a population derived from 14 TIMI clinical trials, CV events caused the majority of deaths post-NSTE-ACS, with recurrent MI representing the most common cause of death within the first 30 days, and sudden death after the first 30 days.
HFpEF: The essentials to know Prof. Burkert Pieske summarizes current treatment strategies for HFpEF and discusses new treatment options that are currently being investigated.
In an observational study,AF was associated with a homogeneously elevated CV risk marker profile in HFrEF patients, whereas in HFpEF, the presence of AF was associated with a more scattered risk marker profile, indicating different underlying pathophysiological mechanisms.
AHA 2018 In the EMPA-HEART Cardiolink-6 trial, 6 months of treatment with empagliflozin reduced LV mass, which may contribute to CV benefits seen in SGLT2i outcome trials.
AHA 2018 Based on the PIONEER-HF results, Larry Allen will now confidently start guideline-recommended therapy in-hospital, for patients with acutely decompensated heart failure.
AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.
AHA 2018 The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.
